The weight-loss drug boom just gained a cheaper challenger in South Africa. India's Sun Pharma has won approval from the health regulator, SAHPRA, to manufacture and sell a generic version of semaglutide, the active ingredient behind Novo Nordisk's blockbuster Ozempic and Wegovy, making South Africa only the second market, after India, where it has cleared the generic.
Why now
The timing is no accident. Novo Nordisk's patent on semaglutide lapsed in March, opening the door to a wave of cheaper copies from local and international drugmakers. Sun Pharma plans to launch within days, selling its version as a pre-filled, multi-dose pen in two strengths, 2mg and 4mg, for once-weekly use. The approval covers adults with inadequately controlled type 2 diabetes. Sun Pharma cast the clearance as proof it can make complex generics to global quality standards, offering the pen at 2mg/1.5mL and 4mg/3mL for flexible weekly dosing.
A crowded, pricey market
South Africa's weight-loss and diabetes market has been dominated by Eli Lilly's Mounjaro and Novo's Ozempic and Wegovy, premium products that have also spawned a grey market of cheaper compounded copies. Regulators have been trying to rein that in, even as demand for lower-cost treatment surges. A licensed generic changes the maths: it offers a cheaper, regulator-approved alternative to both the originators and the compounded knock-offs. "We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals," said Sun Pharma COO Aalok Shanghvi.
For patients priced out of the originals, that competition matters, especially with type 2 diabetes rates climbing in South Africa. The question now is how quickly the generic reaches pharmacy shelves, and how far it pulls down the cost of a treatment that has become as much a lifestyle phenomenon as a medical one.
The entry also turns up the heat on Eli Lilly, whose own diabetes and obesity blockbusters have found a ready South African market. Sun Pharma confirmed the approval on Wednesday and said the same ability to develop complex generics that meet stringent quality standards is what let it clear the drug in a second market so soon after India. For a country facing a rising type 2 diabetes burden, a locally approved, lower-cost semaglutide could widen access well beyond those who can afford the branded originals.
